Close Menu

NEW YORK − Biotech company Kinnate is slowly exiting out of stealth mode with a pipeline that features two targeted drug candidates expected to enter clinical trials next year. The company is particularly eager to explore its lead product, a RAF inhibitor, in non-V600 BRAF-mutated non-small cell lung cancer, colorectal cancer, and melanoma.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.